MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
MetaVia Inc. (MTVA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026 CAMBRIDGE, Mass., October 28, 2026 – MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiome
How this was made
The 30-second read
Why it matters
The announcement provides the first public glimpse of DA‑1726’s Phase 1 efficacy, which could be a catalyst for the stock if data are viewed as compelling.
Market read
First‑time disclosure of early clinical data for a novel obesity drug; potential short‑term price move for MTVA.
What to watch
The trial size is small and comparative data to approved drugs are pre‑clinical; regulatory timeline remains uncertain.
Background
MetaVia (Nasdaq: MTVA) is a clinical‑stage biotech focused on cardiometabolic diseases. The company is developing DA‑1726, a dual GLP‑1/glucagon receptor agonist, and vanoglipel for MASH.
Ticker impact
MetaVia announced that Phase 1 data for its dual GLP‑1/glucagon agonist DA‑1726 will be presented at the Precision Liver Symposium on Nov 4, providing the first public details of the trial results.
likely upward pressure as the market prices in encouraging early‑stage results
First‑time disclosure of trial outcomes for a novel obesity/metabolic drug; biotech stocks typically react strongly to early clinical data.
Market effects
May lift sentiment for obesity and metabolic disease therapeutics, potentially benefiting peers in the GLP‑1/dual‑agonist space.
Limited to US biotech investors; no broader regional effect.
Modest, confined to biotech and specialty pharma investors.
Counterpoint
Phase 1 data are early and may not translate to later‑stage success; investors should weigh execution risk.
Key entities
- companyMetaVia Inc.
Clinical‑stage biotech developing metabolic disease therapeutics.
- drug_candidateDA‑1726
Dual GLP‑1 and glucagon receptor agonist targeting obesity and metabolic disease.
